US 11,746,158 B2
Therapeutic molecules
Brian McGuinness, Cambridge (GB); Isabelle Osuch, Cambridge (GB); Chris Rossant, Cambridge (GB); Mike Romanos, Cambridge (GB); Nikki Royle, Cambridge (GB); Thomas Sandal, Cambridge (GB); Lorraine Thompson, Cambridge (GB); and Michele Writer, Cambridge (GB)
Assigned to Crescendo Biologics Limited, Cambridge (GB)
Filed by CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Filed on Oct. 22, 2021, as Appl. No. 17/508,583.
Application 17/508,583 is a continuation of application No. 16/069,497, granted, now 11,236,174, previously published as PCT/GB2017/050074, filed on Jan. 12, 2017.
Claims priority of application No. 1600559 (GB), filed on Jan. 12, 2016; application No. 1605763 (GB), filed on Apr. 4, 2016; and application No. 1605770 (GB), filed on Apr. 4, 2016.
Prior Publication US 2022/0112305 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 51/10 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 47/68 (2017.01)
CPC C07K 16/3069 (2013.01) [A61K 47/643 (2017.08); A61K 47/644 (2017.08); A61K 47/6415 (2017.08); A61K 47/6425 (2017.08); A61K 47/6801 (2017.08); A61K 47/6811 (2017.08); A61K 47/6815 (2017.08); A61K 47/6817 (2017.08); A61K 47/6869 (2017.08); A61K 47/6887 (2017.08); A61K 47/6889 (2017.08); A61K 51/10 (2013.01); A61P 35/00 (2018.01); G01N 33/57434 (2013.01); C07K 2317/21 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 12 Claims
 
1. A binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody comprising CDR1, CDR2 and CDR3 sequences selected from
a CDR1 sequence comprising SEQ ID NO. 1, a CDR2 sequence comprising SEQ ID NO. 2 and a CDR3 sequence comprising SEQ ID NO. 3, or
a CDR1 sequence comprising SEQ ID NO. 5, a CDR2 sequence comprising SEQ ID NO. 6 and a CDR3 sequence comprising SEQ ID NO. 7, or
a CDR1 sequence comprising SEQ ID NO. 9, a CDR2 sequence comprising SEQ ID NO. 10 and a CDR3 sequence comprising SEQ ID NO. 11, or
a CDR1 sequence comprising SEQ ID NO. 13, a CDR2 sequence comprising SEQ ID NO. 14 and a CDR3 sequence comprising SEQ ID NO. 15, or
a CDR1 sequence comprising SEQ ID NO. 17, a CDR2 sequence comprising SEQ ID NO. 18 and a CDR3 sequence comprising SEQ ID NO. 19, or
a CDR1 sequence comprising SEQ ID NO. 21, a CDR2 sequence comprising SEQ ID NO. 22 and a CDR3 sequence comprising SEQ ID NO. 23, or
a CDR1 sequence comprising SEQ ID NO. 25, a CDR2 sequence comprising SEQ ID NO. 26 and a CDR3 sequence comprising SEQ ID NO. 27, or
a CDR1 sequence comprising SEQ ID NO. 29, a CDR2 sequence comprising SEQ ID NO. 30 and a CDR3 sequence comprising SEQ ID NO. 31, or
a CDR1 sequence comprising SEQ ID NO. 33, a CDR2 sequence comprising SEQ ID NO. 34 and a CDR3 sequence comprising SEQ ID NO. 35, or
a CDR1 sequence comprising SEQ ID NO. 37, a CDR2 sequence comprising SEQ ID NO. 38 and a CDR3 sequence comprising SEQ ID NO. 39, or
a CDR1 sequence comprising SEQ ID NO. 41, a CDR2 sequence comprising SEQ ID NO. 42 and a CDR3 sequence comprising SEQ ID NO. 43, or
a CDR1 sequence comprising SEQ ID NO. 45, a CDR2 sequence comprising SEQ ID NO. 46 and a CDR3 sequence comprising SEQ ID NO. 47, or
a CDR1 sequence comprising SEQ ID NO. 49, a CDR2 sequence comprising SEQ ID NO. 50 and a CDR3 sequence comprising SEQ ID NO. 51, or
a CDR1 sequence comprising SEQ ID NO. 53, a CDR2 sequence comprising SEQ ID NO. 54 and a CDR3 sequence comprising SEQ ID NO. 55, or
a CDR1 sequence comprising SEQ ID NO. 57, a CDR2 sequence comprising SEQ ID NO. 58 and a CDR3 sequence comprising SEQ ID NO. 59, or
a CDR1 sequence comprising SEQ ID NO. 61, a CDR2 sequence comprising SEQ ID NO. 62 and a CDR3 sequence comprising SEQ ID NO. 63, or
a CDR1 sequence comprising SEQ ID NO. 65, a CDR2 sequence comprising SEQ ID NO. 66 and a CDR3 sequence comprising SEQ ID NO. 67, or
a CDR1 sequence comprising SEQ ID NO. 69, a CDR2 sequence comprising SEQ ID NO. 70 and a CDR3 sequence comprising SEQ ID NO. 71, or
a CDR1 sequence comprising SEQ ID NO. 73, a CDR2 sequence comprising SEQ ID NO. 74 and a CDR3 sequence comprising SEQ ID NO. 75, or
a CDR1 sequence comprising SEQ ID NO. 77, a CDR2 sequence comprising SEQ ID NO. 78 and a CDR3 sequence comprising SEQ ID NO. 79.